Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

67%

4 trials in Phase 3/4

Results Transparency

0%

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
4(66.7%)
Phase 2
2(33.3%)
6Total
Phase 3(4)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT00889889Phase 2Completed

Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Adults Aged >= 18 and <= 64, Plus Revaccination

Role: lead

NCT01633749Phase 3Completed

Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 2012/2013 Season

Role: lead

NCT01013675Phase 2Completed

Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Elderly

Role: lead

NCT00881842Phase 3Completed

Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 09/10 Season

Role: lead

NCT00999206Phase 3Completed

Study Measuring the Safety, Immunogenicity and Lot Consistency of Cell Derived Influenza Vaccine

Role: lead

NCT01146015Phase 3Completed

Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 2010/2011 Season

Role: lead

All 6 trials loaded